Durham, N.C. – TruLab is pleased to announce the appointment of Nancy Valente, M.D., to its esteemed board of advisors. With more than two decades of experience in the pharmaceutical and biotechnology industry, Dr. Valente brings a wealth of expertise in clinical development, strategic leadership and innovation.

Dr. Valente’s distinguished career encompasses a series of pivotal roles, including her current tenure as Chief Development Officer at Xencor, where she leads the clinical-stage biopharmaceutical company’s clinical and medical strategy. Prior to joining Xencor’s Board of Directors in 2022, Nancy held several key leadership roles at Genentech (later Roche after it acquired the groundbreaking biotechnology company). Her culminating role as Global Senior Vice President saw her spearhead strategic development initiatives for a diverse portfolio of hematology and oncology therapies. She also served as clinical lead in the acquisition of Spark Therapeutics, a leader in gene therapy, which further underscores her strategic vision and industry acumen.

“We are delighted to welcome Dr. Nancy Valente to TruLab’s Board of Advisors,” said Scott Ogle, CEO and Founder of TruLab. “Nancy’s deep understanding of clinical development and her track record of strategic leadership will be invaluable as we continue to innovate and expand our platform’s capabilities. Her expertise will play a crucial role in guiding TruLab’s growth and impact in the clinical trial ecosystem.”

Dr. Valente’s appointment underscores TruLab’s commitment to excellence and innovation in clinical trial technology. With her strategic guidance, TruLab is poised to drive meaningful advancements in sample management, ultimately benefiting patients, researchers and industry stakeholders alike.

About TruLab:

TruLab, Inc., is a clinical trial technology company that provides cutting-edge solutions for biological sample tracking on blockchain. TruLab’s mission is to help biotechs and pharma track samples in real time, minimize protocol deviations and eliminate paper using innovative mobile technology. Founded in 2018, TruLab is revolutionizing biosample tracking to advance the research and development of new medical therapies. To learn more, visit TruLab.com.